CheckMate-214
Nivolumab + Ipilimumab in Advanced Renal Cell Carcinoma
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 1,096 patients with untreated advanced clear-cell renal cell carcinoma, nivolumab + ipilimumab improved overall survival in intermediate/poor-risk patients compared with sunitinib.
N
1.096
Design
Open-label RCT
Endpunkt
OS, PFS and ORR (co-primary, intermediate/poor risk)
Relevanz
2
ErgebnisIntermediate/poor risk: OS HR 0.63; ORR 42% vs 27% (CR 9% vs 1%). 8-yr median OS 46.7 vs 26.0 months (HR 0.69).
Motzer RJ, et al. N Engl J Med. 2018;378(14):1277-1290. 10.1056/NEJMoa1712126
Diskussion & Kritik
First immunotherapy combination in first-line RCC. Benefit concentrated in intermediate/poor-risk disease — IO+TKI combinations are usually preferred for favourable-risk.